Pier G. Petronini

Parma, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.

Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.

Journal: Oncotarget

Published: April 09, 2026

Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.

Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.

Journal: Breast cancer research and treatment

Published: January 24, 2026

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 13, 2025

Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 15, 2025

Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666.

Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666.

Journal: Cancers

Published: March 04, 2025

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Journal: Frontiers in oncology

Published: November 21, 2024

Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust.

Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust.

Journal: La Medicina del lavoro

Published: June 06, 2024

Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.

Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.

Journal: Biochemical pharmacology

Published: November 06, 2023

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 05, 2023

A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models.

A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models.

Journal: Pharmaceutics

Published: November 03, 2023

PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC).

PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 18, 2023

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.

Journal: Scientific reports

Published: October 05, 2023

Showing 1-12 of 71

Last Updated: 09/26/2026